RESEARCH PAPER

Artificial Intelligence in Gynaecology: A Review of Predictive Models for Early Detection and Management of Ovarian Disorders

Shikha Atteri[1*], Lakshmi Narasimhan srinivasagopalan[2], Dr Bhaskar Jyoti Paul[3]

[1*] Department of Pharmacy, Chandigarh Pharmacy College, CGG University Mohali-140307, Punjab, India, Email ID: shikha.j2589@cgcuniversity.in
[2]Project Manager, Information technology Bharatidasan University, Email ID: narasima_it@yahoo.com
[3]Associate Professor in Obstetrics and Gynecology College of Medicine , University of Shaqra, KSA
Email ID: bjpaul@su.edu.sa

Abstract
Ovarian disorders, such as ovarian cancer, polycystic ovary syndrome (PCOS), and benign ovarian conditions, pose a major challenge in gynaecological practice as they are complex to diagnose and have limitations in terms of early diagnosis. Artificial intelligence (AI) has become an effective solution to these issues as it allows performing high-quality data analysis and enhancing clinical decision-making. This review presents a broad review of the uses of AI to detect and treat ovarian disorders at the early stages, with particular attention to machine learning and deep learning methods. The AI models have proven to be very accurate when it comes to analysing medical images, clinical records, and molecular phenotypes, improving the accuracy of diagnosis and allowing early detection of the disease. Moreover, AI is a key factor in predictive modelling, risk stratification, and personalised treatment planning. The implication of AI in precision medicine development in gynaecology is further emphasised by the incorporation of AI with drug discovery and targeted drug delivery systems. Even with these new developments, issues like data quality, model interpretability, ethical issues, and clinical integration still present major obstacles to the mass implementation. The explainable AI, multi-omics integration, and real-time monitoring advancements in the future will likely improve the clinical utility of explainable AI. All in all, AI can revolutionise the diagnosis and treatment of ovarian disorders with better accuracy, efficiency, and patient outcomes. Further studies and transdisciplinary efforts are needed to realise its full potential in clinical practice.

Keywords: Artificial Intelligence; Ovarian Disorders; Machine Learning; Early Detection; Drug Delivery
How to cite this article: Atteri S, Srinivasagopalan LN, Paul BJ., Artificial Intelligence in Gynaecology: A Review of Predictive Models for Early Detection and Management of Ovarian Disorders. Int J Drug Deliv Technol. 2026;16(45s): 551-564; DOI: 10.25258/ijddt.16.45s.60

1. Introduction

Ovarian disorders are a significant cause of gynaecological morbidity, and a broad range of cancers, polycystic ovary syndrome (PCOS), ovarian cysts, and other functional or structural abnormality occur. The conditions do not only impact on reproductive health, but also with serious systemic complications such as metabolic dysfunction, hormonal imbalance and high risk of death in severe cases. Ovarian cancer is particularly worrying among them because it has a propensity to develop and manifest itself asymptomatically, and because of its late diagnosis which plays a significant role in the high mortality rate and poor survival rates associated with ovarian cancer[1].
Likewise, PCOS, a disease with one of the highest incidences in women of reproductive age, is difficult to diagnose because of its heterogeneous clinical presentation and similarity to other metabolic disorders[2].
The early and precise diagnosis of ovarian diseases is also a significant issue in clinical practice. The traditional diagnostic modalities, such as transvaginal ultrasound, serum biomarkers like CA-125, and clinical examination, are usually limited in terms of their sensitivity, specificity and operator dependence. These techniques might not identify the disease at an early stage or give a false positive outcome, hence postponing the correct intervention or unnecessary procedures[3].

*Author for Correspondence: shikha.j2589@cgcuniversity.in

Moreover, the growing complexity and volume of medical information produced in contemporary healthcare systems have complicated the possibility of clinicians to derive meaningful information when relying solely on traditional methods.
Here, artificial intelligence (AI) has become a strong and disruptive technology that can overcome most of these constraints. AI can be defined as the imitation of human intelligence in machines, which can be accomplished and make decisions with high precision and efficiency. Machine learning (ML) and deep learning (DL) are subfields of AI that have shown tremendous success in large-scale and heterogeneous data processing and are thus highly applicable in medical practice[4]. Such technologies are able to detect complex, non-linear relationships in data that are generally invisible to the human eye and thus can improve diagnostic accuracy and predictive power.
The use of AI in gynaecology has rapidly increased during the last ten years, and both diagnostic and therapeutic areas have been developed significantly. AI systems have been created to help in interpreting images, risk stratification, clinical decision support, and enhance the overall quality of care. Specifically, AI-based predictive modelling has demonstrated a tremendous potential in risk identification of those who are considered high risks of developing an ovarian disorder, which allows initiating a response early[5]. Also,

a more comprehensive and personalised approach to disease management can be achieved through the integration of various data sources, such as imaging, genomics, proteomics, and electronic health records[6].

In recent studies, AI has been emphasised as being vital in gynaecological cancer, particularly in early ovarian cancer diagnosis and prognosis. Such sophisticated methods as radiomics, which derives quantitative characteristics of medical images, and digital pathology, which makes use of high-resolution histopathological data, have greatly increased the capability of identifying subtle patterns of diseases. These methods, along with AI algorithms, have proven to be more diagnostic and prognostic predictions than traditional methods (Maiorano et al., 2025). In addition, AI applications in ultrasound imaging, which is a major diagnostic method in gynaecology, have demonstrated the possibility of enhancing the distinction between benign and malignant ovarian lesions, thus helping to make clinical decisions[7].

In addition to diagnostic use, AI is also under investigation in its ability to optimise therapeutic approaches, and improve precision medicine. Predictive analytics could help clinicians to choose the most successful treatment options, according to patient specificity, which could enhance clinical outcomes and minimise negative effects. Moreover, AI can be used to improve drug delivery by providing targeted and personalised therapeutic modalities, of which are especially applicable in the treatment of ovarian malignancies[8]. Incorporation of AI into new technology like nanomedicine and smart drug delivery systems also highlights how AI can transform gynaecological care[9].

In spite of this encouraging news, the general implementation of AI in gynaecology is not without its problems. Data quality problems, non-standardised datasets, lack of transparency in algorithms, and potential bias in AI models are still crucial issues. Additionally, ethical concerns, such as patient privacy, data protection, and regulatory approval, should be properly considered to guarantee safe and efficient application in clinical practice[10]. It will take a concerted effort on the part of clinicians, researchers, data scientists and regulatory bodies to overcome these barriers.

Considering these developments and issues, there is an increasing necessity of a synthesis of the existing evidence on the role of AI in the early diagnosis and treatment of ovarian disorders. Consequently, the scope of this review is to critically examine AI methods used in gynaecology, how they have been applied clinically to address particular issues in the ovarian disease, and how they might be combined with treatment and drug delivery interventions. The review also identifies the current limitations and provides future directions to support the successful implementation of AI technologies into the ordinary clinical practice.

This study represents specific objectives:

1. To critically analyse the current applications of artificial intelligence in the early detection and diagnosis of ovarian disorders, with a focus on machine learning and deep learning techniques used in clinical and imaging data interpretation.
2. To evaluate the role of AI-driven predictive models in improving clinical decision-making and personalised management of ovarian conditions, including their integration with diagnostic, prognostic, and therapeutic strategies.
3. To explore the potential of artificial intelligence in enhancing drug delivery systems and precision medicine in gynaecology, while identifying existing challenges, limitations, and future research directions for effective clinical implementation.

2. Overview of Artificial Intelligence in Healthcare

2.1 Concept and Scope of Artificial Intelligence in Healthcare

Artificial intelligence (AI) has become a disruptive technology in the contemporary healthcare sector, allowing the creation of systems that can do some tasks that usually involve human intelligence, including learning, reasoning, and decision-making. There is a growing integration of AI technologies in clinical workflows to increase the accuracy of diagnostic, optimise treatment plans, and improve patient outcomes. The increasing use of AI is also largely motivated by the speedy growth in healthcare data, such as electronic health records, medical imaging, and genomic data, which demand sophisticated computing applications to be analysed efficiently[11].

2.2 Machine Learning Approaches in Medicine

Machine learning (ML), which is a core component of AI, deals with creation of algorithms that are capable of learning by data and making predictions or decisions without having explicit programming. The ML methods are broadly divided into supervised, unsupervised and reinforcement learning. Supervised learning models that are trained with labelled datasets are popular in the classification of diseases and prediction of risks. Unsupervised learning, in contrast, finds concealed patterns in unlabelled data and is thus useful in clustering and exploring data. Although reinforcement learning has not been widely used in gynaecology, it is aimed at maximising the sequential learning by means of feedback learning[12]. These methods have greatly led to the development of predictive analytics and clinical decision support systems.

2.3 Deep Learning and Neural Network Architectures

Deep learning (DL), a more modern branch of machine learning, applies multilayer artificial neural networks to complex and high-dimensional data. Convolutional neural networks (CNNs) are one of them that have been shown to be highly effective in the medical analysis of images, especially ultrasound, MRI, and CT scans. By learning and extracting interesting features, CNNs can automatically learn and extract these features in images, which reduces the need to interpret images manually and minimises inter-observer variability[13]. Besides that, recurrent neural networks (RNNs) and hybrid deep learning models are also under consideration as potential ways to analyse sequential and temporal clinical data, which expands the developers of the AI in healthcare.

2.4 Integration of Multimodal Healthcare Data

One of the most significant advantages of AI is its ability to integrate and analyse heterogeneous data sources. These comprise imaging data, genomic and proteomic data, clinical data and real-world patient data. Through the combination of these various datasets, AI systems can produce a holistic understanding of disease mechanisms, risk factors, and individual patient attributes[14]. This multimodal integration is especially useful in complicated situations like in ovarian disorders the diagnosis and treatment involves taking into account various biological, clinical, and environmental factors.

2.5 Applications of AI in Gynaecological Practice

AI has shown significant promise in a range of areas of gynaecology, such as screening of diseases, diagnostic imaging, prediction of prognosis, and surgical planning. A1-powered clinical decision support systems are used to help medical workers establish early patterns of diseases and provide formulated interventions that can help improve clinical efficiency and minimise diagnostic errors[15]. Moreover, AI is also being integrated into the processes of digital pathology and radiology (Figure 2). Histopathological analysis and imaging data can be analysed automatically, leading to more accurate and faster diagnosis, especially in gynaecological tumours[16].

2.6 Role of AI in Predictive Analytics and Precision Medicine

Predictive analytics is one of the most impactful applications of AI in healthcare. With AI models, diseases can be predicted in terms of progression, response to treatment, and outcomes of patients using big data and improved algorithms. The ability aids in the adoption of precision medicine, in which therapeutic plans are customised to the patient profiles[17]. Gynaecology Predictive models have been used to evaluate the behaviour of the tumours, survival, and treatment response, thus enabling a more informed and personalised decision-making in clinical practice (Table 1).

Table 1. Representative studies on artificial intelligence in gynaecology and ovarian disorders

Year	Study focus	Study type	Key contribution	Reference
2020	AI in obstetrics and gynaecology	Review	Described AI as an emerging paradigm in women's health research and clinical practice	4
2021	AI in gynaecologic cancers	Systematic review	Summarised current applications and major implementation challenges in gynecologic oncology	10
2022	AI in gynecologic imaging	Systematic review	Reviewed state-of-the-art imaging applications and future directions	13
2023	AI in obstetrics and gynecology	Comprehensive review	Provided broad overview of AI roles in diagnosis, monitoring, and management	37
2024	AI advancements in gynecology	Comprehensive review	Highlighted diagnostic innovation, workflow enhancement, and future scope	14
2024	Machine learning in gynecological care	Review	Discussed ML-based opportunities in diagnosis and prediction	12
2025	AI in ultrasound for benign gynecological disorders	Systematic review	Demonstrated growing utility of AI-assisted ultrasound in benign gynecologic conditions	7
2025	AI in gynecologic cancer diagnosis and management	Review	Summarized diagnostic, prognostic, and management-related AI applications	34
2025	AI in screening, diagnosis, treatment, and prognosis of gynecologic malignancies	Review	Covered broad translational role of AI across the oncology care pathway	27
2025	AI in gynaecological oncology from diagnosis to surgery	Review	Emphasized integration of AI from diagnostic evaluation to surgical care	31



Figure 1: AI Techniques Hierarchy

3. AI Techniques Used in Ovarian Disorder Detection

3.1 Machine Learning Models for Clinical Prediction

Machine learning (ML) has been widely used to detect and predict the occurrence of ovarian disorders using structured clinical and biochemical information. The classical ML models like logistic regression, support machines (SVM), decision trees and random forest models are commonly applied in classification and risk prediction problems. These models prove really useful in the detection of trends in patient demographics, hormonal profiles and laboratory outcomes to distinguish between normal and pathological conditions. ML-based predictive models have also shown good performance in detecting early signs of malignancy and determining the risk of disease in gynaecological oncology. Such models can combine a variety of clinical variables in order to produce precise predictions, which are likely to facilitate an early diagnosis and prompt intervention[18]. Moreover, in ovarian cancer, the survival outcomes and response to treatment, which is also one of the most commonly used cancers, have also been predicted using ML and, therefore, increased their clinical applicability[19].

3.2 Deep Learning Techniques in Imaging-Based Diagnosis

Deep learning (DL) has transformed medical imaging in terms of automatic feature extraction and the classification of intricate image information with high accuracy. Convolutional neural networks (CNNs) represent the most popular DL models to process imaging modalities, including ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) images. CNN-based models have demonstrated great potential in distinguishing between benign and malignant ovarian masses in the context of detecting ovarian disorders. Such systems are able to identify minute imaging characteristics that are not necessarily seen by human participants, thus enhancing diagnostic accuracy. Meta-analyses have revealed that AI-based imaging models are more effective than conventional diagnostic techniques in detecting ovarian cancer, especially at the initial stages[20]. More so, AI-enabled ultrasound analysis has gained significance, with ultrasound being the imaging modality of choice in gynaecology (Figure 2). State-of-the-art DL architects can improve image perceptions, minimise operator reliance, and offer uniform diagnostic results[21].

Figure 2. Basic AI workflow in ovarian disorder detection

3.3 AI in Biomarker and Genomic Data Analysis

The combination of AI with biomarkers and genomic data has introduced novel opportunities in early diagnosis and accurate diagnosis of ovarian disorders. Complex molecular data, such as gene expression patterns, proteomic signatures, and biomarkers in the bloodstream, can be analysed with AI models to identify patterns in diseases. To illustrate, AI-based systems have been designed to detect risk of ovarian cancer through blood biomarkers, which allow non-invasive and early detection. These methods improve the sensitivity and specificity of the conventional forms of screening by biomarker[22]. Moreover, genomic analysis based on AI has been applied to determine molecular subtypes of ovarian cancer that can be used to guide specific therapeutic solutions.

3.4 AI Applications in Polycystic Ovary Syndrome (PCOS) Detection

The diagnosis and treatment of PCOS, a multifaceted endocrine disorder consisting of hormonal imbalance and metabolic impairment, are also diagnosed and treated using AI techniques. ML and DL models are designed to examine clinical, biochemical and imaging data to be accurately diagnosed. The systems of AI-driven decision support systems have proven to be extremely accurate in detecting PCOS cases based on factors like menstrual abnormalities, hormonal concentrations, and ultrasound results. Such systems may help clinicians to overcome the variability of diagnosis and enhance the consistency of PCOS diagnosis[23]. In addition, AI models are being employed to forecast long-term complications related to PCOS, including cardiovascular risk and insulin resistance.

3.5 Radiomics and Digital Pathology

Radiomics is an emerging field that involves the extraction of quantitative features from medical images, which can then be analysed using AI algorithms. Radiomics have been applied in the treatment of ovarian diseases to determine heterogeneity of tumours, predict malignancy and detect response to treatment. Likewise, AI-assisted digital pathology can be used to automatically analyse histopathological slides to gain more information on tumour morphology and microenvironment. These methods enhance the accuracy of diagnosis and objective evaluation of the characteristics of the disease. Radiomic and pathological analysis using AI demonstrated some positive outcomes in enhancing the early detection and prognosis of ovarian cancer[24].

3.6 Multimodal AI Models

The latest progress in AI has been towards the creation of multimodal models which combine data across various sources, such as imaging, clinical data, and molecular data. These models give a more detailed insight into the disease processes and enhance predictive capabilities. It has been demonstrated that multimodal AI systems can be used to improve diagnostic accuracy and allow more accurate risk stratification in ovarian disorders. These models have the ability to include intricate interactions among biological and clinical variables by using various datasets and, therefore, enable more personalised and effective clinical decisions[25].

AIs such as machine learning, deep learning, radiomics, and multimodal modelling have made great progress in detecting and diagnosing ovarian disorders (Table 2). These methods have better accuracy, early detection and better clinical decision support. Nevertheless, they need further research and validation to be reliable and applicable to regular clinical practice.

Table 2. Major artificial intelligence techniques used in ovarian disorder detection

AI technique	Common data source	Typical application in ovarian disorders	Strengths	References
Logistic regression	Clinical and laboratory data	Risk prediction, classification of benign vs malignant lesions	Interpretable, easy to implement	28
Support vector machine (SVM)	Structured clinical and imaging features	Disease classification and early prediction	Strong performance in smaller datasets	26
Random forest	Mixed clinical and biomarker data	Feature selection, classification, prognosis	Handles nonlinear relationships and multiple predictors	18
Convolutional neural network (CNN)	Ultrasound, MRI, CT, and pathology images	Ovarian mass classification, cancer detection	Excellent for image analysis and automated feature extraction	21
Radiomics-based AI	Imaging-derived quantitative features	Tumour characterisation, malignancy prediction, and prognosis	Captures subtle image patterns not visible to the human eye	46
Biomarker-based predictive modelling	Blood biomarkers, proteomics, genomics	Early screening, prognosis prediction	Minimally invasive, clinically relevant	22
Multimodal AI models	Imaging + clinical + molecular data	Precision diagnosis and treatment planning	Comprehensive, supports precision medicine	25

4. AI in Early Detection of Specific Ovarian Disorders

4.1 Ovarian Cancer

Ovarian cancer is one of the most important gynaecological malignancies, as it is asymptomatic in the initial stages and has a high mortality rate. Early diagnosis drastically enhances survival rates, but traditional diagnostic tools are not usually able to detect the disease at an early stage. Artificial intelligence (AI) has already shown a lot of potential in eliminating these limitations, as advanced data analysis methods allow detecting them early and correctly. Ovarian cancer detection models based on AI have been more frequently implemented as imaging, clinical, and molecular. Complex datasets may be analysed using predictive algorithms to detect subtle patterns with regard to early tumour development. Research has revealed that AI systems can enhance diagnostic accuracy and help clinicians to differentiate between benign and malignant ovarian masses[26]. Moreover, AI-based models have been employed to forecast disease prognosis and survival, thus making clinical decisions more informed. Besides imaging, AI has also been incorporated in digital pathology to help analyse histopathological samples. These methods make it possible to classify and grade tumours in an automated way, minimising diagnostic variability and enhancing clinical practice reliability. In addition, AI predictive models of preoperative evaluation have been designed, which enable clinicians to assess the characteristics of tumours and design adequate surgical procedures.

4.2 Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome (PCOS) is a complex endocrine dysfunction that targets a substantial proportion of women of reproductive age and is linked to reproductive, metabolic and psychological issues. PCOS is hard to diagnose because it has a heterogeneous clinical presentation, which can encompass hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Traditional diagnostic criteria, including the Rotterdam criteria, are based on a synthesis of clinical, biochemical and imaging results, which tends to cause inconsistent diagnosis and late intervention. Artificial intelligence (AI) has become one of the possible solutions to these issues as it allows integrating and analysing multidimensional datasets. AI-based models can handle clinical data, including a history of menstruation, body mass index (BMI), and hormone levels and process them in collaboration with imaging data to produce more accurate and standardised diagnostic results.

These systems make interpretation less subjective and enhance uniformity in various clinical situations. Recent developments in AI have shown that it can diagnose PCOS as well as predict its related complications, such as insulin resistance, type 2 diabetes, and cardiovascular risks. AI models are useful in early detection of high-risk individuals and implementing timely interventions and preventive measures[27]. Moreover, AI-based decision support systems have the potential to support clinicians to customise treatment regimens to fit the profile of each patient, which is part of personalised medicine. Moreover, AI has been utilised in the ultrasound imaging to detect polycystic ovarian morphology automatically. The distribution of follicles and ovarian volume can be analysed accurately with deep learning models without depending on operators, and improving the reliability of diagnosis. Altogether, the introduction of AI into the diagnosis and management of PCOS is one of the important steps to the enhancement of clinical outcomes and lowering the number of complications in the long term.

4.3 Ovarian Cysts and Benign Ovarian Disorders

Benign ovarian diseases such as functional cysts, endometriomas, and other adnexal masses are commonly seen in gynaecological practice. Although the majority of these conditions are non-malignant, it is important to distinguish between the benign and malignant lesions to prevent non-surgical procedures and provide the relevant treatment to the patient. Original methods of diagnosis are very much dependent on imaging, especially ultrasound, which can be influenced by the operator and a wide range of interpretations. The introduction of artificial intelligence (AI) has greatly boosted the diagnosis of benign ovarian disorders through automated and objective analysis of imaging data. The ultrasound images can be analysed by machine learning and deep learning models to extract the complex features, including texture, shape, and vascular patterns, which are hard to measure manually. Following these features are then utilised to categorise ovarian masses with high precision, enhancing differentiation between benign and malignant cases[28].

In addition, AI-driven diagnostic systems have the ability to combine the findings of imaging with clinical and biochemical data to deliver full-scale risk evaluations. This multimodal intervention can be used to further stratify patients, as it can help clinicians decide whether to pursue conservative management or surgery. These systems decrease uncertainty in diagnosis and aid in evidence-based clinical decision-making. Besides enhancing accuracy in diagnosis, AI can simplify clinical processes by saving time in interpreting the images as well as reducing inter-observer differences. It is especially helpful in resource-constrained environments, where availability of specialist radiologists can be a factor. On the whole, AI-based solutions lead to safer and more efficient benign ovarian conditions management.

4.4 Emerging AI Applications in Other Ovarian Conditions

In addition to more well-known diseases like ovarian cancer and PCOS, artificial intelligence is also being investigated in the detection and treatment of other ovarian diseases, including primary ovarian insufficiency and rare gynaecological diseases. Such disorders are usually associated with rather insidious clinical aspects and complex diagnostic assessment, which makes them the right candidates of AI-based analysis. AI models have shown promise in the analysis of hormonal profile, genetic and clinical parameters to detect early indicators of ovarian dysfunction. When it comes to primary ovarian insufficiency, early diagnosis is important in saving fertility and starting a proper hormone treatment. AI-based interventions can be used to recognise vulnerable patients and forecast the progression of the disease, and thus conduct timely clinical intervention[29].

Also, AI has been implemented in the situation of gynaecological emergencies, where the speed of diagnosis and decision-making is acute. Real-time clinical data can be analysed with the help of AI-based tools to aid emergency management, which has been proven to positively influence patient outcomes and decrease the risk of complications[30]. These uses underscore the flexibility of AI in tackling a multitude of clinical conditions than the daily diagnostics. Moreover, new studies are being conducted on the use of AI in combination with wearable devices and telehealth systems to monitor hormonal fluctuations and reproductive health parameters (Table 3). This kind of innovation can help to facilitate continuous monitoring and early diagnosis of ovarian dysfunction, especially among high-risk groups. Altogether, the growing use of AI in various ovarian disorders highlights its possible role in transforming gynaecological care, as it allows for earlier prediction of risks, better management, and assists in the development of individual approaches to treatment (Figure 3).

Table 3. Disease-specific applications of AI in ovarian disorders

Condition	AI application	Clinical utility	Main findings from the literature	References
Ovarian cancer	Image analysis, radiomics, pathology, biomarker prediction	Early detection, malignancy classification, and prognosis	AI improves discrimination between benign and malignant lesions and supports prognosis estimation	49, 20
Epithelial ovarian cancer	Preoperative prediction models	Surgical planning, outcome prediction	AI supports preoperative diagnosis and recurrence/prognosis estimation	22
PCOS	Clinical decision support, predictive analytics, ultrasound interpretation	Diagnosis, complication prediction, management planning	AI improves diagnostic consistency and may support metabolic risk assessment	23
Benign adnexal masses / ovarian cysts	Ultrasound-based classification	Differentiation of benign vs suspicious lesions	AI-assisted sonography improves objective mass assessment	28
Primary ovarian insufficiency	Risk prediction and management support	Early identification and personalised monitoring	AI shows potential for early recognition of ovarian dysfunction	40
Gynaecologic emergencies involving ovarian conditions	Rapid decision support	Timely diagnosis and emergency management	AI may assist in urgent triage and faster decision-making	30



Figure 3: AI Applications in Ovarian Disorders

5. Integration of AI with Drug Delivery and Therapeutic Strategies

5.1 AI in Personalised Treatment Planning

The role of artificial intelligence (AI) in the development of personalised medicine is rapidly gaining importance, especially in the context of ovarian disorders, where patient heterogeneity prominently affects patient treatment. Personalised treatment planning entails the development of therapeutic plans that are differentiated according to patient characteristics like genetic variations, tumour biology, hormonal status and comorbid conditions. Conventional methods tend to be based on generalised clinical guidelines, which might fail to sufficiently reflect inter-patient variation. The AI-based systems can overcome this drawback by converting multidimensional data sets such as clinical history, imaging results, genomic profiles, and treatment responses to create personalised treatment plans. Such systems have the ability to categorise patients into risk groups, anticipate the development of diseases, and recommend the best treatment options. Such models are used in gynaecological oncology to help clinicians choose between surgery, chemotherapy, targeted therapy, or combinations of modalities and enhance precision in therapy[31]. Furthermore, AI allows planning treatment dynamically and adaptively, as it constantly analyses patient data during the treatment process. This enables real-time changes in therapy regimens in response to patient response, toxicity, and disease progression that eventually optimise treatment effectiveness and reduce adverse effects.

5.2 AI in Drug Discovery and Target Identification

AI in the drug discovery process has radically altered the conventional pharmaceutical development process, which can be time-consuming and consumes resources. In gynaecological diseases, AI has the potential to discover new therapeutic targets linked with ovarian disorders by analysing large-scale biological and chemical data within a short time. Through the discovery of major disease-driving molecules, AI promotes the creation of tailored treatment regimens, which will engage particular biological pathways. Also, machine learning algorithms can be used to filter through large collections of chemical compounds to discover potential drug targets with high efficacy and low toxicity profiles. In silico modelling based on AI also allows prediction of drug-target interactions, pharmacodynamics, and even side effects, thus minimizing the use of early-stage experimental trials. This speeds the process of discovery to clinical use and improves the efficiency in the development of therapeutics[32].

5.3 AI-Enhanced Drug Delivery Systems

The combination of AI and sophisticated drug delivery systems is one of the most innovative uses of AI. Drug delivery is also important in the treatment of ovarian disorders, especially ovarian cancer, where delivery to the target site and reduction of systemic toxicity is a significant challenges. AI technologies have the potential to streamline drug delivery systems through modelling and predicting pharmacodynamic and pharmacokinetic behaviour, such as drug absorption, distribution, metabolism, and excretion. The AI can be applied in nanoparticle-based delivery systems to design an optimal carrier with physicochemical characteristics, including particle size, surface charge, and drug release kinetics, to increase tumour targeting and penetration.

In addition, AI models can be used to model the interaction between drug carriers and the tumour microenvironment, leading to the creation of delivery systems in response to certain biological parameters, including pH, enzyme activity, or hypoxia. This results in smart drug delivery system development that can enable controlled and site-specific drug delivery to enhance therapeutic efficacies and minimise side effects. Moreover, AI can enable the personalisation of drug delivery plans according to patient-specific features, contributing to the shift to precision therapies (Figure 4).



Figure 4: AI Integration with Drug Delivery and Therapeutics

5.4 AI in Treatment Response Prediction and Prognosis

Treatment response can only be properly predicted to optimise the therapeutic approaches and enhance patient outcomes in ovarian disorders. Predictive models, AI-based models utilise past and real-time patient data to predict how patients will react to certain treatments, such as chemotherapy, hormone therapy, and targeted agents. These models examine a broad spectrum of variables, including tumour traits, genetic markers, treatment patterns, and previous results to determine patterns that relate to treatment success or failure. This helps clinicians to choose the best therapies and not be exposed to a treatment that is not effective. The AI has been used in ovarian cancer to determine the response to chemotherapy and chances of disease recurrence, which is vital in managing the patient over time. Also, prognostic models have the ability to predict survival and disease progression, which is useful in clinical decision-making and patient counselling[33]. The introduction of AI here does not only increase the accuracy of the treatment but also leads to cost-effective healthcare as it minimizes the trial-and-error model in choosing the treatment.

5.5 Integration with Surgical and Clinical Interventions

Surgical planning and intraoperative decision-making: AI is also transforming the field of gynaecology. Pretreatment evaluation plays a very significant role in the management of ovarian cancer specifically in the establishment of whether complete cytoreductive surgery is possible; this is one of the determinants of patient survival. AI models are able to process imaging, clinical, and tumour features to forecast the outcome of surgery, such as the probability of obtaining optimal cytoreduction. This will allow selection of patients and surgical planning, minimizing operative risk and increasing success rate. Moreover, AI is also being incorporated into robotic and minimally invasive surgeries to make them more precise, minimally complicating, and recovery timesaving. These systems may help surgeons as they offer real-time guidance, analysis of images and forecasts during the procedures. In addition to the surgical procedure, AI-based clinical decision systems can be used to provide all-inclusive management of the patient through the dynamic integration of diagnostic, therapeutic, and prognostic information into a single framework.

6. Advantages of AI in Gynaecological Practice

6.1 Improved Diagnostic Accuracy

Artificial intelligence (AI) can be used to improve the accuracy of the diagnosis, which is one of the most important benefits of AI in gynaecology. Conventional methods of diagnosis tend to be based on the experience of clinicians and their subjective interpretation, which may cause inconsistency and even inaccuracy. With large amounts of data, especially machine learning and deep learning-based AI systems can examine it with high accuracy and detect subtle patterns that a human observer might not notice. In gynaecology, AI has shown better performance in the detection of abnormalities in imaging, histopathology and clinical data. The systems also deliver reproducible and consistent findings, thus decreasing diagnostic discrepancies and enhancing overall clinical reliability[34]. Increased diagnostic accuracy is especially essential in disease conditions, including ovarian cancer, where early diagnosis is a key factor that impacts patient outcomes.

6.2 Early Disease Detection and Risk Stratification

AI allows detecting gynaecological disorders earlier, identifying risk factors and patterns of the disease at an early stage. Through the analysis of patient data, genetic, clinical, and imaging data, AI models have the ability to identify early disease signs before it manifested clinically. This ability facilitates proper stratification of risks, enabling clinicians to classify patients according to their probability of developing certain conditions. Early detection of high-risk people enables timely intervention, which enhances a better prognosis and decreases the burden of diseases[35]. In ovarian disorders, symptoms are usually unspecified and, in these cases, AI-based early diagnosis is essential in enhancing survival and clinical outcomes.

6.3 Enhanced Clinical Decision-Making

Clinical decision support systems (CDSS) based on AI can be of great help to healthcare workers as they offer predictive insights and evidence-based recommendations. These systems combine various data sources to aid in diagnosis, treatment plan and prognosis evaluation. AI-based technologies can help gynaecologists to choose the right diagnosis tests, decide on the best treatment options, and forecast patient outcomes in gynaecological practice. This minimizes the use of subjective judgment and increases the uniformity of clinical decisions[36]. Also, AI systems have the ability to learn with new information continuously, thus enhancing their performance and adjusting to changing clinical practices.

6.4 Increased Efficiency and Reduced Workload

AI in healthcare systems enhances the efficiency of operations greatly by automating operations that are routine and time-consuming. Artificial intelligence (AI) has the potential to help clinicians in gynaecology with image processing, data interpretation, and report-generating tasks, enabling them to concentrate on more complicated patient care. Automation is associated with a shorter diagnosis and treatment planning times, resulting in increased clinical workflow and better patient throughput. This is especially useful in large-volume clinical practices where the scarcity of resources can inhibit the presence of specialised expertise[37]. Moreover, AI eases the further load on medical workers, minimising the number of errors related to fatigue and enhancing productivity in general.

6.5 Support for Precision Medicine

AI is an essential element in promoting precision medicine as it allows personalised treatment methods according to patient-specific features. The AI systems can offer specific therapeutic advice through the combination of various data sets, including genomics, clinical history, and imaging data. In gynaecology, the method is more applicable in the treatment of ovarian disorders because it is possible to choose the treatment which will be most effective in a specific patient. Precision medicine does not only enhance better treatment results but it also minimizes unwarranted interventions, and healthcare expenses[38].

6.6 Cost-Effectiveness and Resource Optimisation

The introduction of AI systems will initially be costly, but the long-term effect of this implementation on healthcare expenses is usually positive. AI enhances efficiency, decreases mistakes in diagnoses, and also decreases the number of unnecessary procedures, which results in cost savings in general. AI has the potential to streamline clinical processes in the gynaecological practice through prioritisation of high-risk patients and optimisation of resources. This is especially significant in the low-resource environments, where the availability of specialised healthcare services can be restricted[39]. AI helps to create more sustainable healthcare systems by enhancing efficiency and minimising waste.

Artificial intelligence has many benefits in the field of gynaecology, such as a more accurate diagnosis, the ability to detect diseases early, a more effective clinical decision-making process, efficiency, and the promotion of precision medicine. All these advantages have led to improved patient outcomes and effective healthcare delivery. With the further development of AI technologies, their implementation in clinical practice is likely to change the gynaecological care even more.

7. Limitations and Challenges of AI in Gynaecology

7.1 Data Quality and Availability

Availability and quality of data is one of the major obstacles to the implementation of artificial intelligence (AI) in gynaecology. The AI models also need vast and high-quality training and validation datasets. But in practice, the data are usually missing, heterogeneous or biased because of differences in data collection procedures and patient groups as well as systems of healthcare. The data with bad quality may have a considerable impact on the accuracy and reliability of AI models and restrict their clinical use. Moreover, AI research utilises many datasets that are based on studies in single centres, and they might not be representative of heterogeneous populations. That is why this inability to be generalised may minimize the efficacy of AI systems in other clinical settings[40]. The availability of standardised, high-quality and varied datasets is an important requirement that ensures the successful implementation of AI in gynaecology.

7.2 Model Interpretability and Transparency

Lack of interpretability is another significant weakness of AI systems and especially deep learning models. A large number of AI algorithms act like black boxes; they produce results without any clear description of how they arrive at decisions. This non-transparency is a great obstacle to clinical adoption, wherein healthcare providers need to have a clear picture of the rationale behind diagnostic or therapeutic advice. The lack of interpretation of AI-generated results in gynaecology, where clinical decisions can have a profound impact on patient outcomes, can decrease clinician trust and limit the adoption of AI in the area. Explainable AI (XAI) methods should therefore be developed to enhance transparency and enable clinical acceptance[41].

7.3 Ethical and Legal Considerations

AI in healthcare touches upon critical ethical and legal issues, especially patient privacy, data security, and informed consent. There are high chances that AI systems need access to vast amounts of sensitive patient data, which can be subject to breaches and misuse of data. Moreover, the issue of responsibility in AI-based decision-making is not addressed. Whenever AI systems give inaccurate or detrimental advice, it is not clear who bears the blame; the developers, clinicians, or the healthcare institutions. It is important to cope with these ethical and legal issues by creating strong regulatory frameworks and guidelines[42].

7.4 Bias and Generalizability Issues

AI models can be biased, which may be due to disproportionate and non-representative training data. These prejudices can result in healthcare disparities, especially when it comes to underrepresented groups. As an illustration, an AI model that has been trained mainly on the data of a particular demographic group might not be effective with other groups. In gynaecology, disease presentation and risk factors could differ among populations, and it is of great importance to ensure that the models are fair and can be generalized. To solve the problem of bias, it is necessary to include a variety of datasets and to introduce strict validation procedures in various clinical settings.

7.5 Integration into Clinical Practice

Although a great progress has been made, it is still difficult to implement AI into everyday clinical workflow. Healthcare systems are frequently under-equipped and lack the technical expertise and interoperability to enable the use of AI. Also, the unwillingness of healthcare professionals to change and fears of substituting human judgment can also become obstacles to change. A successful integration will involve clinicians, data scientists, and healthcare administrators to make sure that AI systems are user-friendly, reliable, and meet clinical demands. The healthcare professionals should also be trained and educated to embrace the use of AI technologies[43].

7.6 Regulatory and Validation Challenges

AI systems should be properly validated before they can be adopted in clinical practice. Nevertheless, AI advancement is often faster than regulatory frameworks are put in place. This poses difficulties in the safety, effectiveness, and reliability of AI-based tools. Regulatory authorities are yet to come up with systems to assess AI technologies, especially those that learn and evolve with time. In gynaecology, where the clinical decision might directly affect patient survival and quality of life, sound validation and regulatory approval are crucial to ensure safe delivery (Table 4).

Table 4. Challenges, limitations, and future directions of AI in ovarian disorder management

Domain	Current challenge	Impact on practice	Future direction	Representative references
Data quality	Small, incomplete, or single-centre datasets	Limits model robustness and external validity	Build multicentre, standardised datasets	29
Bias and generalizability	Underrepresentation of diverse populations	Unequal performance across patient groups	Use diverse and externally validated datasets	6
Interpretability	Black-box nature of deep learning models	Reduces clinician trust and explainability	Develop explainable AI frameworks	10
Clinical integration	Poor workflow integration and low interoperability	Slows adoption in real-world practice	Design user-centred, workflow-compatible tools	43
Ethical and legal issues	Privacy, consent, liability, and data security concerns	Regulatory hesitation and implementation barriers	Stronger governance and regulatory policies	42
Therapeutic translation	Limited prospective validation in drug delivery and treatment optimisation	Restricts routine therapeutic use	Expand translational and	9

			prospective clinical studies	

8. Future Perspectives

8.1 Advancements in Explainable and Trustworthy AI

As artificial intelligence (AI) continues to evolve, one of the key areas of future development is the advancement of explainable and trustworthy AI systems. To improve clinical uptake, it will be necessary to augment transparency and interpretability to encourage clinician confidence. The next generation of AI is likely to have explainability capabilities, which will enable healthcare professionals to get a sense of why a prediction and recommendations were made. This will be of much concern, especially in gynaecology, where clinical decisions have high-risk situations and thus must be well justified[44].

8.2 Integration with Multi-Omics and Big Data

The future of AI in gynaecology is the possibility of combining multi-omics data, such as genomics, proteomics, metabolomics, and transcriptomics, with clinical and imaging data. The holistic approach will facilitate a closer insight into disease mechanisms and help develop highly personalised treatment strategies[45]. The intersection of AI and big data technologies will help to analyse complex biological systems and predict better. Such integration in ovarian disorders can also discover new biomarkers, improve early detection, and direct specific treatment interventions[46].

8.3 AI in Real-Time Monitoring and Digital Health

Emerging technologies such as wearable devices, mobile health applications, and remote monitoring systems are expected to play a significant role in the future of AI-driven gynaecological care. These devices have the potential to gather physiological and behavioural data continuously; this can be analysed with algorithms of AI to identify the first signs of dysfunction in the ovary and track disease progression. Real-time monitoring can also be used to implement proactive healthcare, which can be early intervention and better patient outcome. Moreover, digital health platforms that use AI may increase patient engagement and provide personalised care even beyond a clinical environment[47].

8.4 Advancements in Precision Drug Delivery

It is believed that AI will become a crucial part of the next-generation drug delivery system. The direction of future studies will be the combination of AI and nanotechnology, intelligent biomaterials, and targeted delivery platforms to enable truly specific and effective therapeutic interventions. These systems will be able to adjust to the specifics of patients and dynamic diseases conditions, providing regulated and location-specific drug delivery. Such developments in the case of ovarian disorders would have a profound impact on the effectiveness of treatment in addition to reducing the systemic toxicity, which would beneficially impact the overall results of patients[48].

8.5 Collaborative and Interdisciplinary Approaches

Effective application of AI in gynaecology will be achieved through close coordination between clinicians, data scientists, engineers, and regulatory agencies. The interdisciplinary approaches will be critical to overcome the technical, clinical, and ethical issues related to AI technologies. The way forward should aim at the creation of standardised datasets, regulatory frameworks and education and training of healthcare professionals. These projects will contribute to reducing the disparity between technological development and clinical care and guaranteeing successful AI implementation into practical healthcare[49].

9. Conclusion

Artificial intelligence (AI) has become a revolutionary technology in gynaecology, which brings tremendous progress in the early diagnosis and treatment of ovarian diseases. Through machine learning, deep learning, and multimodal data integration, AI systems have proven to have better abilities in the analysis of complex clinical, imaging, and molecular data. These technologies have been associated with higher accuracy in diagnosis whereby the ovarian conditions can be identified at an earlier stage, which is very important in improving patient outcomes, especially in ovarian cancer. In addition to diagnostics, AI is highly important in the future of personalised medicine as it aids in the development of individualised treatment plans depending on the profile of the patient. Its incorporation into therapeutic planning, drug discovery and drug delivery systems has only reinforced its clinical relevance further as it allows more precise and effective interventions with minimal adverse effects. Moreover, AI-based predictive models have led to improved anticipation of the disease course and response to treatment, which can be used to make informed clinical decisions. Although these developments are promising, the vast implementation of AI in gynaecological practice is crippled by issues including data quality, model interpretability, ethical considerations, and its integration into the existing healthcare systems. To resolve these problems, strong validation, standardised frameworks, and interdisciplinary partnerships of clinicians, researchers, and policymakers are needed. To sum up, AI has a great potential to transform the gynaecological healthcare sector, enhancing the accuracy of diagnostics, optimising treatment options, and promoting precision medicine. As AI continues to be researched, refined, and used responsibly, it will become a part of the future of managing ovarian disorders and eventually improve patient care and clinical outcomes.

References

1. Hong MK, Ding DC. Early diagnosis of ovarian cancer: A comprehensive review of the advances, challenges, and future directions. Diagnostics. 2025 Feb 7;15(4):406.
2. Ghaderzadeh M, Garavand A, Salehnasab C. Artificial intelligence in polycystic ovary syndrome: A systematic review of diagnostic and predictive applications. BMC Medical Informatics and Decision Making. 2025 Nov 24;25(1):427.
3. Mitrofanova PV, Ramazanova KS, Beshkok MB, Goroeva AZ, Sidorenko PO, Khodova ME, Gagloeva KI, Palchaeva AT, Zhukova VS, Merkulova AP. Modern methods of diagnosis of gynecological diseases. Cardiometry. 2024 May 1(31):138-44.
4. Iftikhar P, Kuijpers MV, Khayyat A, Iftikhar A, De Sa MD. Artificial intelligence: a new paradigm in obstetrics and gynecology research and clinical practice. Cureus. 2020 Feb 28;12(2).
5. Rafi AH, Sultana A, Chowdhury AA, Tariq M. Artificial intelligence for early diagnosis and personalized treatment in gynecology. International Journal of Advanced Engineering Technologies and Innovations. 2024;2(1):286-306.
6. Khamisy-Farah R, Furstenau LB, Kong JD, Wu J, Bragazzi NL. Gynecology meets big data in the disruptive innovation medical era: state-of-art and future prospects. International Journal of Environmental Research and Public Health. 2021 May 11;18(10):5058.
7. Moro F, Giudice MT, Ciancia M, Zace D, Baldassari G, Vagni M, Tran HE, Scambia G, Testa AC. Application of artificial intelligence to ultrasound imaging for benign gynecological disorders: systematic review. Ultrasound in Obstetrics & Gynecology. 2025 Mar;65(3):295-302.
8. Wang Q, Zhou X, Wu J, Miao W, Shen B, Shi R. Research progress of artificial intelligence in the early screening, diagnosis, precise treatment and prognosis prediction of three central gynecological malignancies. Frontiers in Oncology. 2025 Sep 9;15:1648407.
9. Shi S, Dai C, Liu D, Liu X. Application of ultrasound in combination with other methods in gynecological disease: artificial intelligence, surgery, and drugs. Frontiers in Oncology. 2025 Sep 1;15:1567024.
10. Akazawa M, Hashimoto K. Artificial intelligence in gynecologic cancers: Current status and future challenges–A systematic review. Artificial Intelligence in Medicine. 2021 Oct 1;120:102164.
11. Patel DJ, Chaudhari K, Acharya N, Shrivastava D, Muneeba S. Artificial intelligence in obstetrics and gynecology: transforming care and outcomes. Cureus. 2024 Jul 17;16(7).
12. Khan I, Khare BK. Exploring the potential of machine learning in gynecological care: a review. Archives of Gynecology and Obstetrics. 2024 Jun;309(6):2347-65.
13. Shrestha P, Poudyal B, Yadollahi S, Wright DE, Gregory AV, Warner JD, Korfiatis P, Green IC, Rassier SL, Mariani A, Kim B. A systematic review on the use of artificial intelligence in gynecologic imaging–background, state of the art, and future directions. Gynecologic oncology. 2022 Sep 1;166(3):596-605.
14. Brandão M, Mendes F, Martins M, Cardoso P, Macedo G, Mascarenhas T, Mascarenhas Saraiva M. Revolutionizing women's health: A comprehensive review of artificial intelligence advancements in gynecology. Journal of Clinical Medicine. 2024 Feb 13;13(4):1061
15. Rahimi M, Kashani K, Hosseinpour V, Gozali E. Artificial Intelligence in Gynecologic Cancer: A Review of Applications and Advancements. Iranian Journal of Blood and Cancer. 2025 Jun 30;17(2):46-57
16. Wang Y, Lin W, Zhuang X, Wang X, He Y, Li L, Lyu G. Advances in artificial intelligence for the diagnosis and treatment of ovarian cancer. Oncology reports. 2024 Mar 1;51(3):1-7.
17. Garg P, Krishna M, Kulkarni P, Horne D, Salgia R, Singhal SS. Machine learning models for predicting gynecological cancers: advances, challenges, and future directions. Cancers. 2025 Aug 27;17(17):2799.
18. Gandotra S, Kumar Y, Modi N, Choi J, Shafi J, Ijaz MF. Comprehensive analysis of artificial intelligence techniques for gynaecological cancer: symptoms identification, prognosis and prediction. Artificial Intelligence Review. 2024 Jul 29;57(8):220.
19. Asadi F, Rahimi M, Ramezanghorbani N, Almasi S. Comparing the effectiveness of artificial intelligence models in predicting ovarian cancer survival: A systematic review. Cancer Reports. 2025 Mar;8(3):e70138.
20. Xu HL, Gong TT, Liu FH, Chen HY, Xiao Q, Hou Y, Huang Y, Sun HZ, Shi Y, Gao S, Lou Y. Artificial intelligence performance in image-based ovarian cancer identification: A systematic review and meta-analysis. EClinicalMedicine. 2022 Nov 1;53.
21. Mitchell S, Nikolopoulos M, El-Zarka A, Al-Karawi D, Al-Zaidi S, Ghai A, Gaughran JE, Sayasneh A. Artificial intelligence in ultrasound diagnoses of ovarian cancer: a systematic review and meta-analysis. Cancers. 2024 Jan 19;16(2):422.
22. Kawakami E, Tabata J, Yanaihara N, Ishikawa T, Koseki K, Iida Y, Saito M, Komazaki H, Shapiro JS, Goto C, Akiyama Y. Application of artificial intelligence for preoperative diagnostic and prognostic prediction in epithelial ovarian cancer based on blood biomarkers. Clinical cancer research. 2019 May 15;25(10):3006-15.
23. Nsugbe E. An artificial intelligence-based decision support system for early diagnosis of polycystic oaries syndrome. Healthcare Analytics. 2023 Nov 1;3:100164.

24. Wang YL, Gao S, Xiao Q, Li C, Grzegorzek M, Zhang YY, Li XH, Kang Y, Liu FH, Huang DH, Gong TT. Role of artificial intelligence in digital pathology for gynecological cancers. Computational and Structural Biotechnology Journal. 2024 Dec 1;24:205-12.
25. Wu M, Zhao Y, Dong X, Jin Y, Cheng S, Zhang N, Xu S, Gu S, Wu Y, Yang J, Yao L. Artificial intelligence-based preoperative prediction system for diagnosis and prognosis in epithelial ovarian cancer: A multicenter study. Frontiers in Oncology. 2022 Sep 21;12:975703.
26. Ayyoubzadeh SM, Ahmadi M, Yazdipour AB, Ghorbani-Bidkorpeh F, Ahmadi M. Prediction of ovarian cancer using artificial intelligence tools. Health Science Reports. 2024 Jul;7(7):e2203
27. Wang J, Chen R, Long H, He J, Tang M, Su M, Deng R, Chen Y, Ni R, Zhao S, Rao M. Artificial intelligence in polycystic ovarian syndrome management: past, present, and future. La radiologia medica. 2025 Sep;130(9):1409-41.
28. Grigore M. Logistic models and artificial intelligence in the sonographic assessment of adnexal masses–a systematic review of the literature. Medical Ultrasonography. 2020 Jan 1.
29. Zhou R, Wei Y, Xiong Y, Su B, Xie J, Hu L, Lei X. Artificial intelligence in primary ovarian insufficiency management: opportunities and challenges. Journal of Assisted Reproduction and Genetics. 2025 Nov;42(11):3581-94.
30. Elbiss HM, Abu-Zidan FM. Artificial intelligence in gynecologic and obstetric emergencies. International Journal of Emergency Medicine. 2025 Feb 10;18(1):20.
31. Restaino S, De Giorgio MR, Pellecchia G, Arcieri M, Vasta FM, Fedele C, Bonome P, Vizzielli G, Pignata S, Giannone G. Artificial intelligence in gynecological oncology from diagnosis to surgery. Cancers. 2025 Mar 21;17(7):1060.
32. Vemulavada, S., Karthikvatsan, S., Babu, A., Kadalmani, B., Devi, T.R., Sasipraba, T., Manikkam, R., Parthasarathy, K. and Balaji, V.H., 2024. Role of artificial intelligence in the diagnosis and therapy of gynecological disorders: opportunities and challenges. *Translational Research in Biomedical Sciences: Recent Progress and Future Prospects*, pp.121-144.
33. Parpinel G, Laudani ME, Piovano E, Zola P, Lecuru F. The use of artificial intelligence for complete cytoreduction prediction in epithelial ovarian cancer: a narrative review. Cancer Control. 2023 Feb 16;30:10732748231159553.
34. Paiboonborirak C, Abu-Rustum NR, Wilailak S. Artificial intelligence in the diagnosis and management of gynecologic cancer. International Journal of Gynaecology & Obstetrics. 2025 Sep;171:199-209.
35. Fazilath M, Umasankar P. Comprehensive Analysis of Artificial Intelligence Applications for Early Detection of Ovarian Tumours: Current Trends and Future Directions. In2025 3rd International Conference on Integrated Circuits and Communication Systems (ICICACS) 2025 Feb 21 (pp. 1-9). IEEE.
36. Khudhur YS. Artificial intelligence in obstetrics and Gynecology: Current applications and future perspectives. International Journal of Obstetrics and Gynaecology. 2025 Jan 1;7(1):12-25.
37. Malani IV SN, Shrivastava D, Raka MS. A comprehensive review of the role of artificial intelligence in obstetrics and gynecology. Cureus. 2023 Feb 12;15(2).
38. Tiwari SW, Bisht K, Joshi M, Chand G, Sagar S, Pandey V. AI-Driven Predictive Modeling: Transforming Diagnosis and Management in Women's Health. In2025 10th International Conference on Smart Structures and Systems (ICSSS) 2025 Dec 12 (pp. 1-9). IEEE.
39. Sawan S, Eftekhari N, Linton-Reid K, Wood N, Numan TA, Aboagye EO, Angione C, Royal College of Obstetricians and Gynaecologists. Artificial Intelligence in Gynaecology Oncology.
40. Zhou J, Zeng ZY, Li L. Progress of artificial intelligence in gynecological malignant tumors. Cancer management and research. 2020 Dec 14:12823-40.
41. Fiste O, Liontos M, Zagouri F, Stamatakos G, Dimopoulos MA. Machine learning applications in gynecological cancer: a critical review. Critical Reviews in Oncology/Hematology. 2022 Nov 1;179:103808.
42. Sivasankari K, Mohan S, Kuppusamy S, Mohan S. Artificial Intelligence in Obstetrics and Gynecology Nursing: Clinical, Educational, and Ethical Perspectives. Cureus. 2026 Mar 28;18(3).
43. Sone K, Taguchi A, Miyamoto Y, Uchino-Mori M, Iriyama T, Hirota Y, Osuga Y. Clinical Prospects for Artificial Intelligence in Obstetrics and Gynecology. JMA journal. 2025 Jan 15;8(1):113-20.
44. Patra S, Shand H, Ghorai S. The role of artificial intelligence (AI) in the early detection of women-specific cancers. Discover Medicine. 2026 Apr 9;3(1):37.
45. Shailieva SL, Mamchueva DK, Vishnevskaya AP, Dzhalaeva KS, Ramazanova EG, Kokaeva YR, Eloeva ZM, Aisanova DR, Vinogradova AS, Tuko RR, Sineva AV. An opportunity for using artificial intelligence in modern gynecology. Obstetrics, Gynecology and Reproduction. 2024 May 6;18(4):563-80.
46. Maiorano MF, Cormio G, Loizzi V, Maiorano BA. Artificial intelligence in ovarian cancer: a systematic review and meta-analysis of predictive AI models in genomics, radiomics, and immunotherapy. AI. 2025 Apr 18;6(4):84.
47. Moro F, Ciancia M, Zace D, Vagni M, Tran HE, Giudice MT, Zoccoli SG, Mascilini F, Ciccarone F, Boldrini L, D'Antonio F. Role of artificial intelligence applied to ultrasound in gynecology

oncology: A systematic review. International journal of cancer. 2024 Nov 15;155(10):1832-45.
48. Sone K, Toyohara Y, Taguchi A, Miyamoto Y, Tanikawa M, Uchino-Mori M, Iriyama T, Tsuruga T, Osuga Y. Application of artificial intelligence in gynecologic malignancies: A review. Journal of Obstetrics and Gynaecology Research. 2021 Aug;47(8):2577-85.
49. Akazawa M, Hashimoto K. Artificial intelligence in ovarian cancer diagnosis. Anticancer research. 2020 Aug 1;40(8):4795-800.